Ribociclib ups survival in postmenopausal Asian women with advanced breast cancer
HONG KONG The cyclin-dependent kinase (CDK) 4/6 pathway inhibitor, ribociclib (LEE011, Novartis AG), in combination with Femara (letrozole, Novartis AG), significantly improved progression-free survival (PFS) in postmenopausal Asian women with advanced breast cancer, in a subanalysis of the MONALEESA-2 trial.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST